These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 30293116)

  • 1. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
    Singh YP; Pandey A; Vishwakarma S; Modi G
    Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
    Gassen M; Youdim MB
    Pharmacol Toxicol; 1997 Apr; 80(4):159-66. PubMed ID: 9140134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
    Apostolakis S; Kypraiou AM
    Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron and Parkinson's disease: chelators to the rescue?
    Levenson CW
    Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
    Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
    Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators.
    Amit T; Avramovich-Tirosh Y; Youdim MB; Mandel S
    FASEB J; 2008 May; 22(5):1296-305. PubMed ID: 18048580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
    Weinreb O; Mandel S; Youdim MBH; Amit T
    Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of iron in brain ageing and neurodegenerative disorders.
    Ward RJ; Zucca FA; Duyn JH; Crichton RR; Zecca L
    Lancet Neurol; 2014 Oct; 13(10):1045-60. PubMed ID: 25231526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New therapeutic strategy for Parkinson's and Alzheimer's disease.
    Esposito E; Cuzzocrea S
    Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
    Beal MF
    J Bioenerg Biomembr; 2004 Aug; 36(4):381-6. PubMed ID: 15377876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.
    Kupershmidt L; Youdim MBH
    Cells; 2023 Feb; 12(5):. PubMed ID: 36899898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C
    Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation and neuroprotection in neurodegenerative diseases.
    Li X; Jankovic J; Le W
    J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.